Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis

Table 1 Ulcerative colitis patient’s data

	1	2	3	4
Age (yr)	37	42	38	36
Sex	Male	Female	Female	Male
Disease’ location	Left side	Extensive colitis	Left side	Left side
Disease activity	Moderate-severe	Severe	Severe	Severe
Time from diagnosis (yr)	2	10	8	22
Truelove index	13	17	14	15
Previous therapy	Corticosteroids azathioprine	Corticosteroids azathioprine	Corticosteroids azathioprine	Corticosteroids azathioprine
Indication for GMA-apheresis	Steroid-dependent disease	Steroid-dependent disease	Steroid-dependent disease	Steroid-dependent disease
Cycles of GMA-apheresis	10	5	7	5
Response to GMA-apheresis	Remission	Response	Failure	Remission
Truelove index (after therapy)	10	10	16	9
Endoscopy	No inflammation	No inflammation	Bleeding ulcers	No inflammation
Recurrences	At 6 mo	At 6 mo		Non

GMA: Granuocyte/monocyte apheresis.

Table 2 Clinical and analytical data of Crohn disease’s patients

	Patient 5		Patient 6
	Pre apheresis	Post apheresis	Pre apheresis	Post apheresis
CDA I	241	161	236	156
Cutaneous lesion	Pyoderma gangrenosum	Healing1	Erythema nodosum	Healing1
Hematocrit	37.5	37.1	32.3	34
Haemoglobin	11.9	11.9	10.6	10.9
GSV	62	39	74	58
C-reactive protein	67	13	17	4
Platelets × 103/mL	241	161	236	151

¹Number of GMA-apheresis sessions to achieve the healing: 13 for PG, 5 for E N.